Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Identifieur interne : 000674 ( PascalFrancis/Corpus ); précédent : 000673; suivant : 000675Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Auteurs : P. Hadji ; M. Ziller ; D. G. Kieback ; W. Dornoff ; H. W. Tessen ; T. Menschik ; J. Kuck ; F. Melchert ; A. HasenburgSource :
- Annals of oncology [ 0923-7534 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 09-0309205 INIST |
---|---|
ET : | Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy |
AU : | HADJI (P.); ZILLER (M.); KIEBACK (D. G.); DORNOFF (W.); TESSEN (H. W.); MENSCHIK (T.); KUCK (J.); MELCHERT (F.); HASENBURG (A.) |
AF : | Department of Gynecology, University Hospital of Giessen and Marburg/Marburg/Allemagne (1 aut., 2 aut.); Helios Kliniken/Aue/Allemagne (3 aut.); Klinikum Mutterhaus der Borromaerinnen/Trier/Allemagne (4 aut.); Onkologische Schwerpunktpraxis/Goslar/Allemagne (5 aut.); Pfizer, Specialty Brand Team Europe/Paris/France (6 aut.); Independent Clinical Research Consulting, Bölschestrasse/Berlin/Allemagne (7 aut.); University of Mannheim/Mannheim/Allemagne (8 aut.); Freiburg University, Frauenklinik/Freiburg/Allemagne (9 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2009; Vol. 20; No. 7; Pp. 1203-1209; Bibl. 30 ref. |
LA : | Anglais |
EA : | Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment. |
CC : | 002B02R; 002B20E02; 002B15A |
FD : | Exémestane; Tamoxifène; Os; Santé; Essai clinique; Allemagne; Prospective; Randomisation; Inhibiteur de l'aromatase; Densité minérale osseuse; Précoce; Cancer du sein; Fracture; Ostéoporose; Anticancéreux |
FG : | Europe; Dérivé de l'androstane; Estrogen synthase; Enzyme; Inhibiteur enzyme; Stéroïde; Antihormone; Antioestrogène; Composé non stéroïde; Modulateur sélectif des récepteurs aux oestrogènes; Système ostéoarticulaire; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie du système ostéoarticulaire; Traumatisme |
ED : | Exemestane; Tamoxifene; Bone; Health; Clinical trial; Germany; Prospective; Randomization; Aromatase inhibitor; Bone mineral density; Early; Breast cancer; Fracture; Osteoporosis; Antineoplastic agent |
EG : | Europe; Androstane derivatives; Estrogen synthase; Enzyme; Enzyme inhibitor; Steroid; Antihormone; Antiestrogen; Non steroid compound; Selective estrogen receptor modulator; Osteoarticular system; Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Diseases of the osteoarticular system; Trauma |
SD : | Exemestano; Tamoxifeno; Hueso; Salud; Ensayo clínico; Alemania; Prospectiva; Aleatorización; Inhibidor aromatase; Masa mineral ósea; Precoz; Cáncer del pecho; Fractura; Osteoporosis; Anticanceroso |
LO : | INIST-22429.354000187188000090 |
ID : | 09-0309205 |
Links to Exploration step
Pascal:09-0309205Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title>
<author><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name>
<affiliation><inist:fA14 i1="02"><s1>Helios Kliniken</s1>
<s2>Aue</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name>
<affiliation><inist:fA14 i1="03"><s1>Klinikum Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name>
<affiliation><inist:fA14 i1="04"><s1>Onkologische Schwerpunktpraxis</s1>
<s2>Goslar</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name>
<affiliation><inist:fA14 i1="05"><s1>Pfizer, Specialty Brand Team Europe</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name>
<affiliation><inist:fA14 i1="06"><s1>Independent Clinical Research Consulting, Bölschestrasse</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name>
<affiliation><inist:fA14 i1="07"><s1>University of Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name>
<affiliation><inist:fA14 i1="08"><s1>Freiburg University, Frauenklinik</s1>
<s2>Freiburg</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0309205</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0309205 INIST</idno>
<idno type="RBID">Pascal:09-0309205</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000674</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title>
<author><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name>
<affiliation><inist:fA14 i1="02"><s1>Helios Kliniken</s1>
<s2>Aue</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name>
<affiliation><inist:fA14 i1="03"><s1>Klinikum Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name>
<affiliation><inist:fA14 i1="04"><s1>Onkologische Schwerpunktpraxis</s1>
<s2>Goslar</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name>
<affiliation><inist:fA14 i1="05"><s1>Pfizer, Specialty Brand Team Europe</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name>
<affiliation><inist:fA14 i1="06"><s1>Independent Clinical Research Consulting, Bölschestrasse</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name>
<affiliation><inist:fA14 i1="07"><s1>University of Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name>
<affiliation><inist:fA14 i1="08"><s1>Freiburg University, Frauenklinik</s1>
<s2>Freiburg</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Aromatase inhibitor</term>
<term>Bone</term>
<term>Bone mineral density</term>
<term>Breast cancer</term>
<term>Clinical trial</term>
<term>Early</term>
<term>Exemestane</term>
<term>Fracture</term>
<term>Germany</term>
<term>Health</term>
<term>Osteoporosis</term>
<term>Prospective</term>
<term>Randomization</term>
<term>Tamoxifene</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Exémestane</term>
<term>Tamoxifène</term>
<term>Os</term>
<term>Santé</term>
<term>Essai clinique</term>
<term>Allemagne</term>
<term>Prospective</term>
<term>Randomisation</term>
<term>Inhibiteur de l'aromatase</term>
<term>Densité minérale osseuse</term>
<term>Précoce</term>
<term>Cancer du sein</term>
<term>Fracture</term>
<term>Ostéoporose</term>
<term>Anticancéreux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0923-7534</s0>
</fA01>
<fA03 i2="1"><s0>Ann. oncol.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HADJI (P.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ZILLER (M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KIEBACK (D. G.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DORNOFF (W.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>TESSEN (H. W.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MENSCHIK (T.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KUCK (J.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MELCHERT (F.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HASENBURG (A.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Helios Kliniken</s1>
<s2>Aue</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Klinikum Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Onkologische Schwerpunktpraxis</s1>
<s2>Goslar</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Pfizer, Specialty Brand Team Europe</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Independent Clinical Research Consulting, Bölschestrasse</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>University of Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Freiburg University, Frauenklinik</s1>
<s2>Freiburg</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>1203-1209</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22429</s2>
<s5>354000187188000090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0309205</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of oncology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02R</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20E02</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B15A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Exémestane</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Exemestane</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Exemestano</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tamoxifène</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Tamoxifene</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tamoxifeno</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Os</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Bone</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hueso</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Santé</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Health</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Salud</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Allemagne</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Germany</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Alemania</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Prospective</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Prospective</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Prospectiva</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Randomization</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Inhibiteur de l'aromatase</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Aromatase inhibitor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inhibidor aromatase</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Densité minérale osseuse</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Bone mineral density</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Masa mineral ósea</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Précoce</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Early</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Precoz</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Cancer du sein</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Breast cancer</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Cáncer del pecho</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Fracture</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Fracture</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Fractura</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Ostéoporose</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Osteoporosis</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Osteoporosis</s0>
<s5>14</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Dérivé de l'androstane</s0>
<s2>FR</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Androstane derivatives</s0>
<s2>FR</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Androstano derivado</s0>
<s2>FR</s2>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Estrogen synthase</s0>
<s2>FE</s2>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Estrogen synthase</s0>
<s2>FE</s2>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Estrogen synthase</s0>
<s2>FE</s2>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Stéroïde</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Steroid</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Esteroide</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Antihormone</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Antihormone</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Antihormona</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Antioestrogène</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Antiestrogen</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Antiestrógeno</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Composé non stéroïde</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Non steroid compound</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Compuesto no esteroide</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Modulateur sélectif des récepteurs aux oestrogènes</s0>
<s5>44</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Selective estrogen receptor modulator</s0>
<s5>44</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Modulador selectivo del receptor de estrógeno</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Système ostéoarticulaire</s0>
<s5>45</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Osteoarticular system</s0>
<s5>45</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Sistema osteoarticular</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>46</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>46</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>46</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="14" i2="X" l="FRE"><s0>Pathologie de la glande mammaire</s0>
<s2>NM</s2>
<s5>47</s5>
</fC07>
<fC07 i1="14" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>47</s5>
</fC07>
<fC07 i1="14" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>47</s5>
</fC07>
<fC07 i1="15" i2="X" l="FRE"><s0>Pathologie du sein</s0>
<s2>NM</s2>
<s5>48</s5>
</fC07>
<fC07 i1="15" i2="X" l="ENG"><s0>Breast disease</s0>
<s2>NM</s2>
<s5>48</s5>
</fC07>
<fC07 i1="15" i2="X" l="SPA"><s0>Seno patología</s0>
<s2>NM</s2>
<s5>48</s5>
</fC07>
<fC07 i1="16" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0>
<s5>49</s5>
</fC07>
<fC07 i1="16" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0>
<s5>49</s5>
</fC07>
<fC07 i1="16" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0>
<s5>49</s5>
</fC07>
<fC07 i1="17" i2="X" l="FRE"><s0>Traumatisme</s0>
<s5>50</s5>
</fC07>
<fC07 i1="17" i2="X" l="ENG"><s0>Trauma</s0>
<s5>50</s5>
</fC07>
<fC07 i1="17" i2="X" l="SPA"><s0>Traumatismo</s0>
<s5>50</s5>
</fC07>
<fN21><s1>222</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0309205 INIST</NO>
<ET>Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</ET>
<AU>HADJI (P.); ZILLER (M.); KIEBACK (D. G.); DORNOFF (W.); TESSEN (H. W.); MENSCHIK (T.); KUCK (J.); MELCHERT (F.); HASENBURG (A.)</AU>
<AF>Department of Gynecology, University Hospital of Giessen and Marburg/Marburg/Allemagne (1 aut., 2 aut.); Helios Kliniken/Aue/Allemagne (3 aut.); Klinikum Mutterhaus der Borromaerinnen/Trier/Allemagne (4 aut.); Onkologische Schwerpunktpraxis/Goslar/Allemagne (5 aut.); Pfizer, Specialty Brand Team Europe/Paris/France (6 aut.); Independent Clinical Research Consulting, Bölschestrasse/Berlin/Allemagne (7 aut.); University of Mannheim/Mannheim/Allemagne (8 aut.); Freiburg University, Frauenklinik/Freiburg/Allemagne (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2009; Vol. 20; No. 7; Pp. 1203-1209; Bibl. 30 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</EA>
<CC>002B02R; 002B20E02; 002B15A</CC>
<FD>Exémestane; Tamoxifène; Os; Santé; Essai clinique; Allemagne; Prospective; Randomisation; Inhibiteur de l'aromatase; Densité minérale osseuse; Précoce; Cancer du sein; Fracture; Ostéoporose; Anticancéreux</FD>
<FG>Europe; Dérivé de l'androstane; Estrogen synthase; Enzyme; Inhibiteur enzyme; Stéroïde; Antihormone; Antioestrogène; Composé non stéroïde; Modulateur sélectif des récepteurs aux oestrogènes; Système ostéoarticulaire; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie du système ostéoarticulaire; Traumatisme</FG>
<ED>Exemestane; Tamoxifene; Bone; Health; Clinical trial; Germany; Prospective; Randomization; Aromatase inhibitor; Bone mineral density; Early; Breast cancer; Fracture; Osteoporosis; Antineoplastic agent</ED>
<EG>Europe; Androstane derivatives; Estrogen synthase; Enzyme; Enzyme inhibitor; Steroid; Antihormone; Antiestrogen; Non steroid compound; Selective estrogen receptor modulator; Osteoarticular system; Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Diseases of the osteoarticular system; Trauma</EG>
<SD>Exemestano; Tamoxifeno; Hueso; Salud; Ensayo clínico; Alemania; Prospectiva; Aleatorización; Inhibidor aromatase; Masa mineral ósea; Precoz; Cáncer del pecho; Fractura; Osteoporosis; Anticanceroso</SD>
<LO>INIST-22429.354000187188000090</LO>
<ID>09-0309205</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000674 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000674 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Rhénanie |area= UnivTrevesV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:09-0309205 |texte= Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy }}
![]() | This area was generated with Dilib version V0.6.31. | ![]() |